SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
A white blood cell charging an ADC/
Antibody-drug conjugate (ADC)
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers.
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Business consultant. Hands help a businessman is falling from a graph vector
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its protein degrader candidate that investors found underwhelming.
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
A Conversation With Kevin Marks, CEO of Delphia
In the second podcast in a special series focused on BioSpace’s NextGen Class of 2025, Senior Editor Annalee Armstrong speaks with Kevin Marks, CEO of Delphia Therapeutics.
March 4, 2025
 · 
1 min read
 · 
Annalee Armstrong
Contemporary art collage of hand holding a dart aiming at the target. Business targeting, aiming, focus concept. Modern design. Copy space.
NextGen
Delphia Eyes New Precision Medicine Approach: Activation Lethality
Delphia launched in May 2024 with the goal of forcing malignant cells to overactivate and die.
March 4, 2025
 · 
2 min read
 · 
Annalee Armstrong
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, with data expected in the first half of 2026.
March 3, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Glitter Vibrant Spheres Abstract Background Digital Renderingv
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their blood removed to bring down dangerously high hemocrit levels.
March 3, 2025
 · 
2 min read
 · 
Annalee Armstrong
Pop art Medicine pill or tablet icon isolated on color background. Capsule pill and drug sign. Pharmacy design. Vector Illustration
Pain
Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure
Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III trials before long.
March 3, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
AbbVie's office in South San Francisco, California
Obesity
Obesity Late-Comer AbbVie Inks up to $2.2B Amylin Deal With Gubra
AbbVie is joining the amylin arena, though the pharma is still far behind leaders Novo Nordisk and Eli Lilly.
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that will apply to all EU member states as well as Norway, Liechtenstein and Iceland.
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS